Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) just unveiled an announcement.
Q-linea AB announced the successful exercise of 91.5% of its series TO1 warrants, resulting in the subscription of nearly 2 billion new shares at SEK 0.03 each, raising approximately 59.5 MSEK before transaction costs. This exercise increases the company’s share capital significantly and results in a dilution effect of about 30.8%, impacting the company’s financial structure and market positioning.
More about Q-linea AB
Q-linea AB is a company listed on Nasdaq Stockholm, primarily operating in the biotechnology industry. The company focuses on developing and providing innovative diagnostic solutions, particularly in the field of infectious diseases.
Average Trading Volume: 39,558,278
Current Market Cap: SEK204.2M
See more insights into QLINEA stock on TipRanks’ Stock Analysis page.